You are here: Industry Insights > Teva Pharmaceutical

News List

Teva shares approach 20-year low amid Moody's warning and other woes fiercepharma
August 18, 2019
Teva Pharmaceutical CEO Kåre Schultz has gone to great lengths to shave off $3 billion in costs by instituting a major restructuring plan that has included slashing 14,000 jobs and shuttering manufacturing plants around the world.
Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville pharmafocusasia
April 19, 2019
Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville.
Teva hit with $6.3M retaliation verdict in age, anti-American discrimination suit fiercepharma
December 05, 2018
Only months after a judge ruled that Teva must face a lawsuit from former manager Stephen Middlebrooks alleging retaliation, age discrimination and anti-American bias, jurors ruled in favor of the plaintiff and ordered...
Richmond-based E. Claiborne Robins Co. Inc. lawsuit against Teva Pharmaceutical seeks $110 million firstwordpharma
December 02, 2018
Former specialty drug company E. Claiborne Robins has filed a $110-million lawsuit suit against Teva in a dispute over a 2007 asset purchasing agreement, reported Richmond.com.
Israeli unions warn Teva Pharmaceutical biospectrumasia
April 17, 2018
Half of the factory’s 175 workers would lose their jobs in the coming months, with the rest continuing to work until the plant closes.
Bidders line up for Teva's women's health unit in potential $2B sale fiercepharma
August 23, 2017
Teva may sell it's women's health unit intact or split it up between U.S. and European assets, Bloomberg's sources say.
A 10 years' Top 10 patent losses worth a tremendous $915B in lifetime sales fiercepharma
August 18, 2017
The top patent losses of the last 10 years have bring that situation to new—even record-setting—heights.
Teva Pharmaceutical launches generic allergic eye treatment Pataday in US pharmaceutical-technology
June 14, 2017
Israeli-based Teva Pharmaceutical Industries has launched its generic of Novartis’ eye drop medication Pataday (olopatadine hydrochloride ophthalmic solution) 0.2% in the US.